European Archives of Psychiatry and Clinical Neuroscience is a prominent peer-reviewed journal published by Springer Heidelberg, focusing on the interdisciplinary aspects of psychiatry and clinical neuroscience. With an ISSN of 0940-1334 and an E-ISSN of 1433-8491, this journal provides a rigorous platform for innovative research spanning biological psychiatry, pharmacology, and various aspects of mental health. The journal boasts a distinguished impact factor that places it in the Q2 category for Biological Psychiatry and Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health as of 2023, reflecting its significant contribution to the field. Additionally, its Scopus rankings highlight its esteemed position among the top journals, particularly in Medicine and Neuroscience disciplines. Readers can access a wealth of valuable research articles, case studies, and reviews, crucial for advancing understanding and treatment within these vital fields. Initially converged in 1990, the journal continues to evolve and support scholarly dialogue until 2024 and beyond, making it an essential resource for researchers, clinicians, and students alike.

Neurobiology of Stress is an esteemed open-access journal dedicated to advancing the field of stress research, published by ELSEVIER SCIENCE INC. Since its inception in 2015, the journal has rapidly ascended in academic prestige, achieving a remarkable Q1 ranking across multiple categories, including Biochemistry, Cellular and Molecular Neuroscience, and Endocrinology, among others. With an impact-driven approach, it focuses on the intricate mechanisms of stress response at molecular, cellular, and systemic levels, making it an essential resource for researchers, professionals, and students alike. The journal fosters interdisciplinary collaboration and innovation, providing a platform for cutting-edge studies and critical reviews that address the complexities of stress biology. As part of its commitment to accessibility, all published articles are freely available, ensuring that groundbreaking findings reach a global audience. Join a community at the forefront of stress research and contribute to the vital conversations shaping our understanding of neurobiological processes.

Annals of Indian Psychiatry is a premier journal dedicated to the field of mental health and psychiatry, published by Wolters Kluwer Medknow Publications. As an Open Access journal since 2017, it provides a platform for disseminating high-quality research articles, clinical studies, and reviews that address the diverse aspects of psychiatric disorders, treatment methodologies, and mental health policy in India and beyond. The journal aims to bridge gaps in the existing literature, support practitioners with evidence-based insights, and foster dialog among researchers in the psychiatric community. With an emphasis on innovative approaches and culturally relevant practices, the Annals of Indian Psychiatry serves as a vital resource for psychiatrists, psychologists, social workers, and students engaged in clinical practice and academic research. Its commitment to improving mental health outcomes in diverse populations makes it a significant contributor to the global discourse on psychiatric health.

Alpha Psychiatry, published by AVES, stands at the forefront of mental health research and psychiatric advancements. With a commitment to disseminating high-quality and impactful studies, this journal serves as a critical platform for scholars, clinicians, and students interested in exploring the complexities of psychiatric disorders and treatment methodologies. Although the impact factor and specific scope details are still evolving, Alpha Psychiatry is dedicated to fostering interdisciplinary dialogue and promoting innovative research that tackles contemporary challenges in the field of psychiatry. As an open-access journal, it ensures that research is widely accessible, enhancing knowledge transfer and collaboration within the global scientific community. Located in Istanbul, Turkiye, the journal proudly represents a rich academic tradition, aiming to contribute significantly to the global discourse on mental health.

Schizophrenia Research-Cognition is an esteemed journal dedicated to advancing the understanding of cognitive aspects of schizophrenia and related mental health disorders. Published by Elsevier, this Open Access journal has been a pivotal platform since its inception in 2014, facilitating the dissemination of high-quality research findings to a global audience. With a notable impact factor and categorized in the Q2 quartile for both Cognitive Neuroscience and Psychiatry and Mental Health, it ranks among the top journals in these fields, currently positioned at #171 out of 567 in Psychiatry and at #40 out of 115 in Cognitive Neuroscience according to Scopus metrics. Located in the United States, and published under the auspices of Elsevier, the journal aims to provide an insightful forum for researchers, clinicians, and students interested in the cognitive underpinnings of schizophrenia, promoting innovative research that bridges the gap between cognitive neuroscience and clinical application. Schizophrenia Research-Cognition's commitment to open access ensures wide-reaching impact and engagement from the research community and beyond.

Asia-Pacific Psychiatry is a leading academic journal published by WILEY, focused on the diverse and rapidly evolving fields of psychiatry and mental health within the Asia-Pacific region. With an ISSN of 1758-5864 and an E-ISSN of 1758-5872, this journal has been recognized for its significant impact, holding a Q1 ranking in Medicine (miscellaneous) and a Q2 ranking in Psychiatry and Mental Health as of 2023. Its commendable Scopus ranking places it at Rank #83 out of 567 in its category, highlighting its influence and relevance in contemporary research. The journal aims to facilitate the dissemination of high-quality research, reviews, and clinical insights that address mental health challenges, promote global understanding, and encourage collaboration among professionals and academics. Although it is not an open-access journal, the high impact factor underscores its value in the scholarly community, making it an essential resource for researchers, clinicians, and students dedicated to enhancing mental health practices and policies in the region and beyond.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

Biological Psychiatry-Cognitive Neuroscience and Neuroimaging is a leading interdisciplinary journal published by Elsevier, focusing on the convergence of biological psychiatry, cognitive neuroscience, and advanced neuroimaging techniques. With its prestigious Q1 rankings across essential categories such as Biological Psychiatry, Cognitive Neuroscience, and Neurology (clinical), this journal is at the forefront of research that examines the complexities of mental health through innovative methodologies. Covering a broad spectrum of topics from neurobiological mechanisms to clinical applications, it aims to provide a platform for scholars and practitioners to exchange insights on mental disorders and their neurobiological underpinnings. The impact factor and Scopus rankings further underscore its importance, with rankings highlighting its position in the top percentiles of related disciplines. By fostering an open exchange of ideas and promoting cutting-edge research, this journal is an essential resource for researchers, professionals, and students dedicated to advancements in the understanding and treatment of psychiatric and neurological conditions.

Brain and Behavior is a premier open-access journal published by WILEY, dedicated to advancing the field of Behavioral Neuroscience. With its ISSN 2162-3279, the journal has established itself as a vital resource for researchers, professionals, and students alike, fostering the dissemination of cutting-edge research since its inception in 2011. Renowned for its rigorous peer-review process, it enjoys a commendable Q2 ranking within the field, reflecting its impactful contributions and relevance in the scientific community. The journal not only emphasizes innovative studies that bridge behavioral science and neuroscience but also serves as a platform for diverse methodologies and interdisciplinary approaches. Accessible [open access](https://onlinelibrary.wiley.com/journal/21623279), Brain and Behavior invites submissions that explore the neural mechanisms underlying behavior, aiming to engage a global audience eager to expand the boundaries of knowledge in this dynamic field. Positioned in the heart of the United States, at 111 River St, Hoboken, NJ, it is strategically placed to collaborate with leading institutions and researchers worldwide.

PSYCHOPHARMACOLOGY is a leading peer-reviewed journal specializing in the field of pharmacology, specifically focusing on the effects of drugs on behavior, cognition, and emotion. Published by Springer, this esteemed journal has established itself as a pivotal resource for researchers and professionals since its inception in 1959, maintaining its relevance and rigor in the ever-evolving landscape of psychopharmacological research. With an impressive impact factor and ranking in the top quartile (Q1) of the Pharmacology category in 2023, it consistently publishes high-quality studies that contribute to both academic inquiry and clinical practice. The journal's scope includes original research, theoretical papers, and reviews, fostering a multidisciplinary dialogue among psychologists, psychiatrists, pharmacologists, and neuroscientists. As the field of psychopharmacology continues to grow, PSYCHOPHARMACOLOGY remains dedicated to disseminating innovative findings, operationalizing complex concepts, and enhancing the understanding of drug mechanisms and their implications for mental health. This commitment to excellence positions PSYCHOPHARMACOLOGY as an indispensable tool for those seeking to advance their knowledge and research in pharmacology.